Clinical Trial Detail

NCT ID NCT02557321
Title PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Provectus Pharmaceuticals
Indications

melanoma

Therapies

PV-10

Pembrolizumab

Age Groups: adult

No variant requirements are available.